The Effects Of Yangxinshi On Hemodynamics, Anxiety And Depression In Patients With Chronic Heart Failure

Objective: To investigate the effects of Chinese patent medicine Yangxinshi on hemodynamics,anxiety and depression in patients with chronic heart failure(CHF).Methods: From October 2017 to May 2018,patients admitted to the Department of Cardiology of Zhongshan Hospital affiliated to Dalian University for acute decompensated heart failure,80 patients were selected for a stable condition of 2 to 4 weeks,and were willing to sign informed consent to participate in this study.Eighty patients were randomly divided into control group(n=30),Yangxinshi group(n=30),Trimetazidine group(n=10),Yangxinshi+Trimetazidine group(n=10).The following hemodynamic indexes were measured by non-invasive cardiac hemodynamic detector: left ventricular ejection fractionand(LVEF),stroke volume(SV),heart rate(HR),cardiac output(CO),left ventricular end-diastolic volume(LVEDV).Enzyme-linked immunosorbent assay(ELISA)was used to detect oxidative stress related enzymes: Catalase(CAT),Succinic dehydrogenase(SDH),Glutathione peroxidase(GsH-Px),Malonaldehyde(MDA),Superoxide dismutase(SOD).Self-rating Anxiety Scale(SAS)and self-rating Depression Scale(SDS)were used to evaluate the status of anxiety and depression.The quality of life was assessed using the innesota living with heart failure questionnaire(MLHFQ).Patients’ exercise tolerance was assessed with a 6-minute walking test(6-MWT).SPSS24 statistical processing software was applied,and t-test was used to conduct a before-and-after comparison analysis of the baseline period and 6-month follow-up indexes.One-way ANOVA analysis was used for comparison between groups.The Clinical trail has been registered(Registration Number: NCT03333499)and approved by Ethics Committee of our hospital.Results: 1.At the baseline,there were no statistical differences in cardiac hemodynamics,oxidative stress related enzymes,6-MWT walking distance,SAS,SDS,MLHFQ scores between the control group,Yangxinshi group,Trimetazidine group,Yangxinshi +Trimetazidine group.2.Control group: The 6-month follow-up oxidative stress related enzymes and MLHFQ scores were significantly improved compared with the baseline period(P<0.05),while there was no significant difference in other indicators(P>0.05).The indexes of Yangxinshi group,Trimetazidine group,Yangxinshi group+Trimetazidine group were significantly improved compared with the baseline(P<0.05).3.Comparison of6-month follow-up group: Compared with the control group,LVEF,SV,CO,LVEDV and CAT,SDH,GsH-Px and SOD were significantly increased in the other three groups(P<0.05),while MDA and MLHFQ were significantly decreased(P<0.05),There was no significant difference between the three groups(P>0.05).Compared with the control group,the SAS and SDS of the Yangxinshi and Yangxinshi+Trimetazazine groups were significantly reduced(P<0.05),but there was no statistical difference in the Trimetazidine group(P>0.05).Conclusion: 1.After 6 months of treatment with Yangxinshi and Trimetazidine,it was found that both of them could significantly improve cardiac hemodynamics,exercise tolerance and quality of life of CHF patients on the basis of optimized drug treatment,and the combined application of the two drugs had no additional benefits compared with the single drug.2.Yangxinshi can significantly improve the anxiety and depression of CHF patients,but trimetazidine as not been found to have this effect.